Edition:
United States

XOMA Corp (XOMA.OQ)

XOMA.OQ on NASDAQ Stock Exchange Global Market

20.15USD
4:00pm EDT
Change (% chg)

$1.16 (+6.11%)
Prev Close
$18.99
Open
$18.93
Day's High
$20.45
Day's Low
$18.89
Volume
85,916
Avg. Vol
37,897
52-wk High
$20.45
52-wk Low
$3.99

Chart for

About

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA... (more)

Overall

Beta: 3.10
Market Cap(Mil.): $144.29
Shares Outstanding(Mil.): 7.60
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.38 16.25
EPS (TTM): -- -- --
ROI: -- 2.96 14.87
ROE: -- 4.74 13.89

BRIEF-XOMA Earns $3 million milestone payment from its license agreement with Nanotherapeutics

* XOMA earns $3 million milestone payment from its license agreement with nanotherapeutics Source text for Eikon: Further company coverage: [XOMA.O ]

Sep 11 2017

BRIEF-Novartis Pharma reports a 6.6 percent passive stake in Xoma Corp as of August 24, 2017

* Novartis Pharma AG reports a 6.6 percent passive stake in Xoma Corp as of august 24, 2017 - SEC filing‍​ Source text for Eikon: (http://bit.ly/2gEet2Y) Further company coverage:

Sep 05 2017

BRIEF-Xoma announces transformational license agreements for gevokizumab and its IL-1 beta intellectual property portfolio

* Xoma announces transformational license agreements for gevokizumab and its IL-1 beta intellectual property portfolio

Aug 25 2017

BRIEF-XOMA earns $10 mln milestone payment as a licensed asset advances into clinical development

* XOMA earns $10 million milestone payment as another of its licensed assets advances into clinical development Source text for Eikon:

May 18 2017

BRIEF-Xoma Q1 loss per share $2.37

* Q1 basic and diluted net loss per share available to common shareholders of $2.37

May 09 2017

BRIEF-Xoma announces positive results from its phase 2 study of prolactin inhibition

* Xoma announces positive results from its phase 2 proof-of-concept study of prolactin inhibition

Apr 24 2017

BRIEF-Xoma receieves notice to terminate license agreement from Novo Nordisk

* Xoma -on april 20, 2017 co received notice from Novo Nordisk a/s, relating to termination of exclusive license agreement with co due to strategic and business reasons

Apr 21 2017

BRIEF-Xoma presents positive data from PTH1R monoclonal antibody program

* Xoma presents positive data from PTH1R monoclonal antibody program

Apr 18 2017

BRIEF-Xoma announces full repayment of Hercules Technology Growth Capital debt obligation

* Xoma announces full repayment of hercules technology growth capital debt obligation

Mar 22 2017

Competitors

  Price Chg
Albireo Pharma Inc (ALBO.OQ) $22.48 +0.47

Earnings vs. Estimates